Clinical trials: Adult Depression
Major Depressive Disorder and Irritability
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
- Trial name
- NCT02212613
- Testing
- Brexpiprazole
- Where
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD).
- Trial name
- NORLIGHT (NCT07284667)
- Testing
- ACP-211
- Where
- 28 sites in United States
- Volunteers
- 153 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Bipolar Depression
Quetiapine Efficacy in Bipolar Depression Study
To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression
- Trial name
- QUEEN (NCT00523601)
- Where
- 3 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Affective Psychosis, Bipolar, Manic Disorder
Phase 3 /Seroquel SR Acute Mania Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks.
- Conditions
- Affective Psychosis, Bipolar, Manic Disorder, Manic-Depressive Psychosis, Mania
- Trial name
- NCT00422123
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 51 sites in United States
- Volunteers
- 447 people
- Sponsor
- AstraZeneca
Depression, Anxiety
A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health
Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy…
- Conditions
- Depression, Anxiety, Post Traumatic Stress Disorder
- Trial name
- NCT05604794
- Testing
- Ketamine-Assisted Psychotherapy (KAP)
- Where
- 11 sites in United States, Canada
- Volunteers
- 1,806 people
- Sponsor
- Field Trip Health
Major Depressive Disorder
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
- Trial name
- NCT04007367
- Testing
- SAGE-217
- Where
- 46 sites in United States
- Volunteers
- 53 people
- Sponsor
- Biogen
Major Depressive Disorder
Efficacy of Seroquel SR in Combination With an Antidepressant in Treatment of Major Depressive Disorder
To evaluate the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR) in the treatment of Major Depressive Disorder. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation.
- Trial name
- AMBER (NCT00351169)
- Testing
- Quetiapine SR, Escitalopram
- Where
- 42 sites in Canada, China and 7 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Cancer, Psycho-Oncology
What Impact Does an Initial Psycho-oncological Contact Have on People With Cancer?
When diagnosed with cancer, patients or their relatives may, if they wish, on the recommendation of the treatment team and/or in cases of high stress, seek psycho-oncological support.
- Trial name
- PICS (NCT07544446)
- Testing
- initial psycho-oncological contact, Standard
- Where
- 5 sites in Switzerland
- Volunteers
- 148 people
- Sponsor
- Lindenhofgruppe AG
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
- Trial name
- NCT06267846
- Testing
- NBI-1070770
- Where
- 13 sites in United States
- Volunteers
- 73 people
- Sponsor
- Neurocrine Biosciences
Affective Psychosis, Bipolar, Depression, Bipolar
Phase III/Seroquel SR Bipolar Depression Monotherapy - US
The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Depression for 8 weeks.
- Conditions
- Affective Psychosis, Bipolar, Depression, Bipolar, Manic-Depressive Psychosis, Psychoses, Manic-Depressive
- Trial name
- NCT00422214
- Testing
- Quetiapine fumarate (Seroquel) SR
- Where
- 54 sites in United States
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Major Depressive Disorder (MDD)
A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder
This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-blind, placebo-controlled parallel-group study with a 6-week duration.
- Trial name
- NCT07741240
- Testing
- KH607 tablets
- Volunteers
- 232 people
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Depressive Disorder, Major
Zelquistinel in the Treatment of Major Depressive Disorder
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
- Trial name
- AGN-241751 (NCT03586427)
- Testing
- AGN-241751
- Where
- 25 sites in United States
- Volunteers
- 251 people
- Sponsor
- Syndeio Biosciences, Inc
Major Depressive Disorder
Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
The purpose of this study is to compare the efficacy of vortioxetine versus desvenlafaxine after 8 weeks of treatment in patients that have tried one available treatment without getting the full benefit
- Trial name
- VIVRE (NCT04448431)
- Testing
- Vortioxetine, Desvenlafaxine
- Where
- 80 sites in Argentina, Belgium and 10 more
- Volunteers
- 605 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder
MDD POC Study GSK372475 Subjects Depressive Disease
To evaluate the efficacy, safety and tolerability of GSK372475 compared with placebo in the treatment of outpatients subjects with major depressive disorder to exhibit decreased pleasure, interest and energy.
- Trial name
- NCT00420641
- Testing
- GSK372475, Paroxetine
- Where
- 33 sites in Bulgaria, Canada and 8 more
- Volunteers
- 492 people
- Sponsor
- GlaxoSmithKline
Adult
Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in China
Objectives: Primary: To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.
- Trial name
- NCT00478829
- Where
- 15 sites in China
- Volunteers
- 8,000 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Anxiety Depression
Effectiveness and Safety of Probiotics in Relieving Anxiety and Depression
To evaluate the effectiveness and safety of probiotics in relieving anxiety and depression in adults, in comparison with placebo.
- Trial name
- NCT06629441
- Testing
- Probiotic group
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Depressive Disorder, Major
A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an…
- Trial name
- NCT03227224
- Testing
- JNJ-42847922
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 287 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD…
- Trial name
- NCT02371980
- Testing
- Vortioxetine
- Where
- 79 sites in United States
- Volunteers
- 1,106 people
- Sponsor
- Takeda